R & D

Integrity, passion, professionalism, respect and cooperation

Address: No. 1000, North of Shengzhou Avenue, Shengzhou City, Zhejiang Province, China
Tel: +86-575-83123228
Fax: +86-575-83101736
E-mail: hr@alkpharm.cn
URL:

The current position : Home  »   R & D   »   R&D platform

       Our new drug R&D platform is based on the research institute and supported by the quality and production departments in the process of industrialization of research and development results. The main research scope of the institute is chemical quality control research, chemical raw material drug technology research, chemical preparation technology research, new auxiliary materials application research, clinical research, product registration and so on.

 

       The R&D platform adheres to the principle of open cooperation, and relies on the research institutes of well-known colleges and universities at home and abroad to make full use of social resources, carry out research and development of new drugs. Zhejiang Anglikang Pharmaceutical Co., Ltd. is a key enterprise research institute of Zhejiang Province, a key new material research institute of Zhejiang Province, a post-doctoral workstation for enterprises, and an expert workstation for enterprise academicians.

 

       The Institute currently has 50 personnel, 30% of whom are masters or have intermediate titles. It has 100 sets of large and medium-sized instruments, including 30 sets of imported high-end analytical instruments. The Institute consists of Quality Research Institute, API Research Institute, Formulation Research Institute, New Materials Research Institute, Pilot Workshop, Clinical Department, Registration Department and other departments.

 

       The R&D platform undertakes the company's new drug research and development, consistency evaluation, research and development of new pharmaceutical excipients, and solves the technical problems that arise in the company's daily production process.

 

       The R&D platform mainly engages in drugs for cardiovascular diseases, infectious diseases, for digestive diseases, and central nervous diseases. Under the premise of doing a good job in evaluating the quality and efficacy of listed products, we will do a good job in the research and development of generic drugs, and at the same time carry out research and development of improved new drugs and innovative drugs, enrich the company's product line, enhance profitability and benefit the society.

 

       The R&D platform currently has 28 research projects, including 12 consistency evaluation projects, 8 generic drug research and development projects, 6 process improvement projects, and 2 innovative drugs.Among them, the clinical research has been completed and five clinical researches are underway. It is estimated that in 2019, three varieties and five specifications will be reviewed by the national consistency evaluation. The company's main product, levamlodipine besylate tablets, is in a leading position, in the evaluation of consistency.

Link:

Copyright(C)2018, All Rights Reserved. Supported by   Copyright Notice

「5分时时彩平台」浙公网安备 33068302000230号